Skip to main content
Midas Edge

10x Genomics, Inc.

For the period ended Mar 31, 2026. Filed May 8, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 8, 2026

TXG$62.90-3.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share data)

Common Stock · Additional Paid-inCapital · AccumulatedDeficit · AccumulatedOther ComprehensiveIncome (Loss) · TotalStockholders’Equity
Shares · Amount
Balance as of December 31, 2025127,691,329$2$2,306,690$(1,510,591)$225$796,326
Issuance of Class A common stock related to equity awards900,221—273——273
Issuance of Class A common stock for settlement of contingent consideration396,584—8,699——8,699
Stock-based compensation——22,607——22,607
Net loss———(13,470)—(13,470)
Other comprehensive loss————(111)(111)
Balance as of March 31, 2026128,988,134$2$2,338,269$(1,524,061)$114$814,324
Common Stock · Additional Paid-inCapital · AccumulatedDeficit · AccumulatedOther ComprehensiveIncome (Loss) · TotalStockholders’Equity
Shares · Amount
Balance as of December 31, 2024122,291,837$2$2,177,672$(1,467,047)$(493)$710,134
Issuance of Class A common stock related to equity awards841,913—422——422
Stock-based compensation——30,571——30,571
Net loss———(34,358)—(34,358)
Other comprehensive income————126126
Balance as of March 31, 2025123,133,750$2$2,208,665$(1,501,405)$(367)$706,895
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.